Cited by 207Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Open access

Kornauth, Christoph, Pemovska, Tea, Vladimer, Gregory I., Bayer, Günther, Bergmann, Michael, Eder, Sandra, Eichner, Ruth, Erl, Martin, Esterbauer, Harald, Exner, Ruth, Felsleitner-Hauer, Verena, Forte, Maurizio, Gaiger, Alexander, Geissler, Klaus, Greinix, Hildegard T., Gstöttner, Wolfgang, Hacker, Marcus, Hartmann, Bernd Lorenz, Hauswirth, Alexander W., Heinemann, Tim, Heintel, Daniel, Hoda, Mir Alireza, Hopfinger, Georg, Jaeger, Ulrich, Kazianka, Lukas, Kenner, Lukas, Kiesewetter, Barbara, Krall, Nikolaus, Krajnik, Gerhard, Kubicek, Stefan, Le, Trang, Lubowitzki, Simone, Mayerhoefer, Marius E., Menschel, Elisabeth, Merkel, Olaf, Miura, Katsuhiro, Müllauer, Leonhard, Neumeister, Peter, Noesslinger, Thomas, Ocko, Katharina, Öhler, Leopold, Panny, Michael, Pichler, Alexander, Porpaczy, Edit, Prager, Gerald W., Raderer, Markus, Ristl, Robin, Ruckser, Reinhard, Salamon, Julius, Schiefer, Ana-Iris, Schmolke, Ann-Sofie, Schwarzinger, Ilse, Selzer, Edgar, Sillaber, Christian, Skrabs, Cathrin, Sperr, Wolfgang R., Srndic, Ismet, Thalhammer, Renate, Valent, Peter, van der Kouwe, Emiel, Vanura, Katrina, Vogt, Stefan, Waldstein, Cora, Wolf, Dominik, Zielinski, Christoph C., Zojer, Niklas, Simonitsch-Klupp, Ingrid, Superti-Furga, Giulio, Snijder, Berend, Staber, Philipp B.·2022·Cancer Discovery

DOI 10.1158/2159-8290.cd-21-0538PMC PMC9762339

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Abstract Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers. Significance: This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assay-based scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient's cancer. See related commentary by Letai, p. 290. This article is highlighted in the In This Issue feature, p. 275

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0538

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. EXALT procedure and primary outcome measure. A, Viable cells from lymph node (LN), BM, or PB of patients with late-stage hematologic cancer were subjected to image-based scFPM. Target cells are identified by staining with fluorescent antibodies. Reports, automatically generated by the analysis pipeline, are discussed in a dedicated tumor board with patients treated accordingly. B, Our primary outcome measure was PFS ratio, defined as PFS(scFPM treatment)/PFS(previous treatment). A ratio of 1.3 is considered individually beneficial. DAPI, 4′,6-diamidino-2-phenylindole.CC BY-NC-ND · PubMed Central

Figure 2. CONSORT diagram of study patients.CC BY-NC-ND · PubMed Central

Figure 3. scFPM-guided treatment enhances PFS ratio in patients with advanced hematologic cancers and provides a survival benefit. A, Bar plot showing the PFS for all included, scFPM-guided patients: blue bars denote PFS in days for scFPM-guided treatment, red bars indicate last previous treatment, and asterisks denote ongoing response for scFPM treatment at the censoring date. PFS ratio is the following ratio: PFS(scFPM treatment)/PFS(previous treatment). Patient characteristics are color coded and stratified (leukemia vs. lymphoma, exceptional response vs. nonexceptional response, ECOG >1 vs. ECOG ≤1). B, Kaplan–Meier plot comparing PFS on scFPM-guided treatment with previous treatment in exceptional responders (n = 12). C, Bar plot showing PFS for all patients with an ECOG ≤1 (n = 39). Asterisks denote ongoing response for scFPM treatment at censoring date. D, Kaplan–Meier plot comparing PFS on scFPM treatment between patients with ECOG ≤1 (n = 39) versus ECOG>1 (n = 17). E, Bar plot showing PFS for all patients with OR on previous treatment. Asterisks denote ongoing response for scFPM treatment at censoring date. F, Kaplan–Meier plot comparing PFS on scFPM treatment stratified according to OR on last treatment (CR/PR: n = 27, SD/PD: n = 29). G, Scatter plot comparing PFS on last treatment to current treatment, for scFPM-guided versus physician's choice patients (paired Wilcoxon test). H, Kaplan–Meier plot comparing overall survival stratified according to scFPM-guided patients (n = 56) versus physician's choice patients (n = 20).CC BY-NC-ND · PubMed Central

Figure 4. Post hoc analysis. A, Kaplan–Meier plot comparing scFPM-matched treatment with previous treatment. Dotted line denotes 1-year follow-up. B, Kaplan–Meier plot comparing non–scFPM-matched treatment with previous treatment. C, Paired scatter plot comparing nonmatched versus matched patients with regard to PFS ratio. Paired Wilcoxon test comparing PFS of previous treatment versus scFPM-matched/nonmatched treatment [H0: rank PFS(previous) = rank PFS(current)]. D, Kaplan–Meier plot of scFPM-matched treatment stratified according to ECOG <1 versus ECOG ≥1. E, Kaplan–Meier plot of scFPM-matched treatment stratified according to response on previous treatment. F, Kaplan–Meier plots comparing PFS for scFPM-matched patients stratified according to tumor cell content in the sample (high ≥50%, medium >10%, low ≥10%).CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938 · cited 2×
“Response evaluation was based on RECIL criteria for lymphoma and ELN criteria for 468 leukemia (42,43).”
Method
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · cited 1×
“The median time from sampling to scFPM report was 5 (1189 33) days, with longer times accounting for re-staining due to updated immunophenotyping 190 data, and to treatment 21 (4-77) days.”
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765 · cited 2×
“The median time from sampling to scFPM report was 5 (1189 33) days, with longer times accounting for re-staining due to updated immunophenotyping 190 data, and to treatment 21 (4-77) days.”
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755 · cited 1×
“For T-NHL, 9 months of PFS was considered exceptional, and for aggressive B-NHL and myeloid disease, 18 months was considered exceptional based on the definition by Wheeler and colleagues (26) and others (18, 43, 44).”
Background
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E. A., Abel, M. L., et al. (2018) · Nature · doi:10.1038/s41586-018-0623-z · Cited by 1,359 · cited 1×
“The median time from sampling to scFPM report was 5 (1189 33) days, with longer times accounting for re-staining due to updated immunophenotyping 190 data, and to treatment 21 (4-77) days.”
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137 · cited 2×
“therapeutic outcome impossible at our current state of knowledge (3).”
Background
BRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V. A., Schiavoni, G., Holmes, A. B., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,029 · cited 1×
“Genomic tumor characterization and treatment matching have improved the management of some patients with hematologic malignancies, such as BRAF in hairy cell leukemia (11, 12), IDH1/2 in acute myeloid leukemia ABSTRACT Personalized medicine aims to match the right drug with the right patient by using specific features…”
Background
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 803 · cited 2×
“In contrast, a major 315 setback uniformly described in other personalized medicine trials is patient deterioration or 316 death during time of analysis (4,33).”
Background
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Massard, C., Michiels, S., Ferté, C., Deley, M. L., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E. E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 802 · cited 2×
“The median time from sampling to scFPM report was 5 (1189 33) days, with longer times accounting for re-staining due to updated immunophenotyping 190 data, and to treatment 21 (4-77) days.”
Background
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M. C., Hahn, M. E., Williams, C. B., De, P. K., Krie, A. K., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 726 · cited 3×
“329 This strategy could raise the limited matching numbers, but has not yet been validated in a 330 prospective fashion (28).”
Background

Show all 43 references

Research works printed but not linked: 1

Swerdlow, 2017, WHO classification of tumours of haematopoietic and lymphoid tissues. Rev. 4th ed

Sorted by citations

Items 101–200 of 207

Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine
Kordyukova, M., Bulgakov, T. K., Sorokina, M. A., Kudryashova, O. M., Abakumova, T. O., Meshcheryakova, V., Grigoriev, I. V., Senko, I. V., Shevchenko, E. K., & Belousov, V. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052207 · Cited by 6
“These approaches have been validated in hematological malignancies [302] and in a range of solid tumors, including ovarian, breast, colorectal, and head and neck cancers [303].”
A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML
Sahib, N. R. B. M., Mohamed, J. S., Rashid, M. B. M. A., Jayalakshmi, Lin, Y. C., Chee, Y. L., Fan, B. E., Mel, S. D., Ooi, M. G. M., Jen, W., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70401 · Cited by 5
“While these studies show that FPM approaches are beneficial [21], they are usually dependent on single drug sensitivity results that may not recapitulate combinatorial drug sensitivity [26, 27] or may rely on extensive molecular profiling that requires long turnaround time [28–30].”
Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities
Hochman, M. J., Muñiz, J. P., & Papadantonakis, N. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15020049 · Cited by 5
“It was evaluated in multiple aggressive hematologic malignancies in the EXALT trial [198] and SMARTrial [199], and was assessed in AML patients in the DARTT-Figure for Therapy Choice (“MyeloMATCH”) study hopes to take a rigorous precision-based approach for patients, evaluating patients within a…”
Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0492 · Cited by 6
“Our findings are consistent with other published reports and further support the incorporation of rigorous ex vivo functional testing in precision medicine approaches (53, 54).”
Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine
Nössing, C., Herek, P., Shariat, S. F., Berger, W., & Englinger, B. (2024) · Current Opinion in Urology · doi:10.1097/mou.0000000000001177 · Cited by 5
Functional personalized complex combination nano therapy for osteosarcoma
Bar-Natan, O., Harris, Y., Sason, H., & Shamay, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-20222-3 · Cited by 5
“Our findings align with Kornauth et al. 17 , who demonstrated that functional precision medicine provides clinical benefit in aggressive hematologic cancers by identifying unexpected drug sensitivities that genomic profiling alone could not predict.”
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies
Nikanjam, M., & Kurzrock, R. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.004 · Cited by 4
Functional drug screening of tumor organoids on an active-matrix digital microfluidic chip for cancer precision medicine
Sun, R., Feng, Z., Wu, T., Ding, F., Wu, Y., Jin, K., Li, L., Jia, Z., Gao, R., Cong, Y., et al. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01215-2 · Cited by 6
“Functional precision medicine methods involve exposing tumor cells to therapeutic agents and rapidly assessing their response, thereby elucidating patterns of drug sensitivity and resistance without requiring prior knowledge of the underlying molecular vulnerabilities 6,7.”
Microfluidic and organ-on-a-chip approaches to model the tumor microenvironment
Bonnet, V., Angelidakis, E., Sart, S., & Baroud, C. N. (2025) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2025.100606 · Cited by 7
In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis
Chaves, B., Silva, J. C. S. E., Nakaya, H. I., Socquet-Juglard, N., Bucciarelli, F., Prunier, G., Almeida, M. V., Lacouture, C., Kari, S., Astier, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60224-3 · Cited by 4
“The potential of HCI to provide support for treatment decision has recently been highlighted by its ability to predict drug ef ﬁ cacy in patients with hematological cancers 26,33 .”
Ex vivo discovery of synergistic drug combinations for hematologic malignancies
Ali, K. A., Shah, R. D., Dhar, A., Myers, N. M., Nguyen, C., Paul, A., Mancuso, J. E., Patterson, A., Brody, J. P., & Heiser, D. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.001 · Cited by 4
“With this approach to personalized medicine, selected therapies guided by DSS improved survival of patients with hematologic malignancies [24].”
Background
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)
Berghoff, A. S., Mair, M. J., Spiró, Z., Malak, C. A., Heliebi, A. E., Eckert, F., Furtner, J., König, F., Leibetseder, A., Nowosielski, M., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf056 · Cited by 4
“24,25 Notwithstanding, as we were aiming to design a study applicable and feasible for clinical routine, we decided to use the objective and robust ATP measurements as a readout.”
Establishing predictive machine learning models for drug responses in patient derived cell culture
Abdel‐Rehim, A., Orhobor, O. I., Griffiths, G., Soldatova, L., & King, R. D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00937-2 · Cited by 6
“6 The Alan Turing Institute, London, UK. e-mail: aar52@cam.ac.uk based on their ex vivo performance, as opposed to standard treatments 7 – 9 .”
A high-throughput 3D culture microfluidic platform for multi-parameter phenotypic and omics profiling of patient-derived organoidsPreprint
Botrugno, O. A., Bianchi, E., Bruno, J. M., Gallo, G. F. M., Felici, C., Sommella, E., Stefano, P. D., Giansanti, V., Rossella, V., Merciai, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.28.630600 · Cited by 4
Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma
Lee, R. X., Rashid, M. B. M. A., Sahib, N. R. B. M., Goh, J., Mel, S. D., Batumalai, Y., Jayalakshmi, Chua, R., Poon, L. M., Chan, E. H. L., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00780 · Cited by 3
Predicting drug‐perturbed transcriptional responses using multi‐conditional diffusion transformer
Hu, Q., Chen, Z., & Gu, J. (2025) · Quantitative Biology · doi:10.1002/qub2.70016 · Cited by 6
“Drug ‐ perturbed transcriptomes can comprehensively depict the mechanism of action of drugs and play a significant role in the fields of personalized medicine [1, 2] and new drug discovery [3].”
PatientProfiler: building patient-specific signaling models from proteogenomic data
Lombardi, V., Rocco, L. D., Meo, E., Venafra, V., Nisio, E. D., Perticaroli, V., Nicolaeasa, M. L., Cencioni, C., Spallotta, F., Negri, R., et al. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00160-y · Cited by 3
The functional imperative in high-grade glioma
Goh, L. S. H., Thng, D. K. H., Ang, Y. L. E., Ho, D., Toh, T. B., & Wong, A. L. A. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01614-x · Cited by 3
“Notably, 23% of patients remained progression-free at 12 months after FPO-guided therapy, signi ﬁ cantly outperforming the 5% progression-free rate observed with previous treatments 86 .”
Influential
Let’s get functional: Drug sensitivity profiling to enable precision sarcoma medicine
Ball, C. R., & Fröhling, S. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.09.006 · Cited by 3
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
Hermansen, J. U., Athanasiadis, P., Yin, Y., Rise, A.-S. F., Arribas, A. J., Cascione, L., Russnes, H. G., Helland, Å., Mato, A. R., Bertoni, F., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07884-7 · Cited by 3
Preserving potential: Surgeons as key partners in establishing a living sarcoma biobank for translational research purposes
Gijsels, S., Vekeman, M., Fischer, S., Creytens, D., Ackerman, A., Ongenaet, A., Boi, L., Segers, E., Temmerman, J. D., Casteur, F., et al. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102209 · Cited by 2
Ex Vivo Drug Screening: An Emerging Paradigm in the Treatment of Childhood Cancer
Ahmed, A., Cox, E., Lane, L., Rominiyi, O., Danson, S. J., Bryant, H. E., Wells, G., & King, D. A. (2025) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000003017 · Cited by 2
Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma
Tan, P. K., Martins, T. J., Becker, P. S., Wechsler‐Reya, R. J., & Crawford, J. R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1606575 · Cited by 2
The role of advanced diagnostics on precision medicine in hemato oncology
Mandefro, B., Berta, D. M., Kelem, A., Teketelew, B. B., Melkamu, A., Much, Y., Mulatie, Z., & Adane, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-03169-9 · Cited by 2
Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics
Struyf, N., Gezelius, H., Lundmark, A., Barizza, C., Ploeger, H., Pizarro, L. R., Vesterlund, M., Mermelekas, G., Österroos, A., Bohlin, A. B., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01363-8 · Cited by 2
“In line with other functional precision medicine studies 19 – 21 , our ﬁ ndings indicate that ex vivo drug testing may re ﬂ ect clinical response.”
A roadmap of therapeutic strategies for patients with multiple myeloma
(2023) · Nature Cancer · doi:10.1038/s43018-023-00545-8 · Cited by 2
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits
Hahn, C. K., Palmer, A. C., & Weinstock, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.005 · Cited by 2
Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia
Beinortas, T., & Huntly, B. J. P. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101565 · Cited by 2
Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma
Roos-Mattila, M., Kallio, P., Luck, T. J., Polso, M., Kumari, R., Mikkonen, P., Välimäki, K. E., Malmstedt, M., Ellonen, P., Pellinen, T. S., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07004-9 · Cited by 2
“Integration of omics data at the pathway level gives insight into the molecular pathways of patient-speci ﬁ c drug responses Functional ex vivo DSRT empowers ﬁ nding new molecular vulnerabilities and supports the clinical decision-making for personalized treatment 35 – 38 .”
Ex vivo imaging-based high content phenotyping of patients with rheumatoid arthritis
Kartnig, F., Bonelli, M. M., Goldmann, U., Mészáros, N., Krall, N., Aletaha, D., Heinz, L. X., & Superti‐Furga, G. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105522 · Cited by 2
Self-citation
Precision Medicine in Oncology and Cancer Therapeutics
Geantă, M., Боата, А., Brand, A. M., Cucoş, B., & Lehrach, H. (2022) · Springer eBooks · doi:10.1007/978-981-19-5082-7_3 · Cited by 2
Targeting tumour-intrinsic neural vulnerabilities of glioblastomaPreprint
Lee, S., Weiß, T., Bühler, M., Mena, J., Lottenbach, Z., Wegmann, R., Sun, M., Bihl, M., Augustynek, B., Baumann, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.07.511321 · Cited by 2
Self-citation
Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC TrialPreprint
Hall, P. E., Williams, M., Peerani, E., Tham, E. L., Iori, F., de Fraine, G. R. T. B., Loughrey, K. L., Kaffa, A. D., Richardson, T. D. L., Liberal, C., et al. (2024) · medRxiv · doi:10.1101/2024.10.25.24314885 · Cited by 2
“Other work is mainly focused in hematological malignancies (22) and most previous work on FPM has been limited by the inability to include the impact of immunotherapy-based drugs.”
Background
Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens
Tomska, K., Scheinost, S., Kivioja, J. L., Kummer, S., Do, T. H. L., & Zenz, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4188-0_11 · Cited by 1
The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines
Trin, K., Dalleau, C., Mathoulin-Pélissier, S., Tourneau, C. L., Dinart, D., & Bellera, C. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01667-1 · Cited by 1
“» [ 176 ] any prospective trial that relied on a sample size estimation process based on GMI modelling.”
Stratégie intégrée de prise en charge des LAL-T en rechute/réfractaires au laboratoire
Courtois, L., Lhermitte, L., & Asnafi, V. (2025) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(25)76375-3 · Cited by 1
Neural Vulnerabilities in Glioblastoma: Rethinking Therapy Through Neuroactive Drug Repurposing
Colobon, P. O., & Lee, S. (2025) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2025.0024 · Cited by 1
Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors
Adefolaju, A., Kram, D. E., Mann, B., Hingtgen, S., & Satterlee, A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115736 · Cited by 1
Drug screening reveals differential drug response in primary and metastatic clear cell sarcoma
Vejzović, D., Karner, C., Fechter, K., Ritter, G., Holzer, V., Barones, L., Schweintzger, N. A., Wagner, K., Lyssy, F., Gauster, M., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218131 · Cited by 1
Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing
Chan, M., & Gujral, T. S. (2025) · Oncogene · doi:10.1038/s41388-025-03637-0 · Cited by 1
Leveraging AI for cell biology discovery
Simizo, A., de Morais, M., Vesco, M. F. [., & Nakaya, H. I. (2026) · Biochemical Society Transactions · doi:10.1042/bst20253023 · Cited by 1
“Exscientia has developed the first functional precision oncology platform using AI, with several AI-designed compounds currently in clinical development [88,89].”
Biomarkers and advances in AML-MRC: from bench to bedside
Meng, F., Al-Khafaji, Z., Muzammil, K., Sarbazjoda, E., Khaksari, M. N., Bayani, A., & Samarkhazan, H. S. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06805-8 · Cited by 1
An ex vivo functional biomarker of treatment response in pediatric low-grade glioma
Artz, N., Mann, B., Ebbs, A., Darawsheh, R., Dasari, R., Adefolaju, A., Bell, N., Trembath, D. G., Higgins, D. M. O., Elton, S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0331423 · Cited by 1
Integration and validation of complementary ex vivo assays for functional precision oncology
Loboda, A., Paluncic, J., Freitas, M., Weidmann, M., Herter, S., Zeiser, C., Schulz, J. P., Jády, A., Blattner-Johnson, M., Autry, R. J., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01555-2 · Cited by 1
“The high potential of FPO is highlightedby the growing number of precisiononcology programs 10,11 and clinical trials employing FPO strategies 1,12,13 .”
Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues
Meszaros, N., LIND, K., Sehlke, R., Vilagos, B., Krall, N., Vladimer, G. I., & Sill, H. (2022) · British Journal of Haematology · doi:10.1111/bjh.18557 · Cited by 1
Self-citation
Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives
Valent, P., Sadovnik, I., Peter, B., Ivanov, D., Schulenburg, A., Hadzijusufovic, E., Willmann, M., Rülicke, T., Herrmann, H., Rabitsch, W., et al. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2232545 · Cited by 1
Self-citation
VenEx precisely predicts ven-aza response
Becker, P. S. (2025) · Blood · doi:10.1182/blood.2024027054 · Cited by 1
News on Peripheral T-cell lymphoma
Pichler, A. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00864-z · Cited by 1
“Especially the heterogeneous subgroup of patients with T cell lymphomas demonstrated a benefit in median PFS compared to B-cell malignancies [16].”
ResultSelf-citation
Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemiaPreprint
Yin, Y., Athanasiadis, P., Karlsen, L., Urban, A., Murali, I., Fernandes, S. M., Arribas, A. J., Hilli, A. K., Taskén, K., Bertoni, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.14.488428 · Cited by 1
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axisPreprint
Njouendou, A. J., Tiofack, A. A. Z., Kenfack, R. N., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., & Lueong, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.09.495487 · Cited by 1
Clinical Forecasting using Ex Vivo Drug Sensitivity Profiling of Acute Myeloid LeukemiaPreprint
Andersen, A. N., Brodersen, A. M., Durán, P. A., Piechaczyk, L., Tadele, D. S., Baken, L., Fredriksen, J., Stoksflod, M., Lenartova, A., Fløisand, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.11.509866 · Cited by 1
Efficacy and feasibility of Pharmacoscopy-guided treatment for acute myeloid leukemia patients that exhausted all registered therapeutic optionsPreprint
Schmid, J. A., Festl, Y., Severin, Y., Bacher, U., Kronig, M.-N., Snijder, B., & Pabst, T. (2023) · medRxiv · doi:10.1101/2023.03.28.23287745 · Cited by 1
Self-citation
Clonal morphology-guided combination therapies overcome heterogeneity-driven drug tolerancePreprint
Li, X. W., Liu, L., Yan, Y., Yang, M., Luo, L., Jiang, Y., & Ren, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.31.703021 · Cited by 1
“Several clinical studies have demonstrated that treatment plans based on FPM results can improve patient outcomes 6 – 8 .”
Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsPreprint
Paluncic, J., Carrero, Z. I., Fischer, L. K., Schulz, J. P., Hanf, D., Jády, A., GutierrezTenorio, F., Klimova, A., Dagostino, C., Wolf, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.705724 · Cited by 1
Pharmakoskopie-geführte Therapie: Wenn einzelne Zellen den Behandlungsplan vorgeben
Zylka-Menhorn, V. (2021) · Deutsches Ärzteblatt · doi:10.3238/personko.2021.11.26.06
Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen
Hoffmann, J. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_148-1
A novel classification based on non-apoptosis cell death predicts clinical outcomes and immunotherapy response of clear renal cell carcinoma.
Chen, L.-X., Liu, X.-D., Zeng, S.-J., Zhu, H., Wang, J., & Jiang, Q. (2022) · PubMed Central
Data from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Yin, Y., Athanasiadis, P., Karlsen, L., Urban, A., Xu, H., Murali, I., Fernandes, S. M., Arribas, A. J., Hilli, A. K., Taskén, K., et al. (2023) · doi:10.1158/1078-0432.c.6532718
Data from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Yin, Y., Athanasiadis, P., Karlsen, L., Urban, A., Xu, H., Murali, I., Fernandes, S. M., Arribas, A. J., Hilli, A. K., Taskén, K., et al. (2023) · doi:10.1158/1078-0432.c.6532718.v1
Data from Optimizing precision medicine for breast cancer brain metastases with functional drug response assessment.
Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · doi:10.1158/2767-9764.c.6689056.v1
Data from Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · doi:10.1158/2767-9764.c.6689056
A New Microfluidic Device to Facilitate Functional Precision Medicine Assays
Manzano-Muñoz, A., Yeste, J., Ortega, M. A., Samitier, J., Ramón‐Azcón, J., & Montero, J. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3593-3_8
Pharmacogenomics
Kager, L., & Evans, W. E. (2024) · doi:10.1002/9781394180486.ch23
Additional file 7 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623367
Maligne Lymphome – Quo vadis?
Alig, S., Pott, C., & Chapuy, B. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2160-5397
“Einen ebenfalls sehr pragmatischen Weg hat die EXALT-Stu-die beschritten [20].”
Background
The cellular hierarchy of acute myeloid leukemia informs personalized treatmentPreprint
Severin, Y., Festl, Y., Benoit, T. M., Wegmann, R., Hale, B. D., Roiss, M., Kienzler, A., Pabst, T., Scharl, M. M., Sunagawa, S., et al. (2024) · medRxiv · doi:10.1101/2024.07.24.24310768
“For example, we have developed pharmacoscopy, a high-throughput ex vivo drug sensitivity screening platform with single-cell resolution, which showed promising potential to guide treatment selection leading to improved overall survival in AML patients 18,19,23,26 .”
MethodSelf-citation
Patient-derived Organoids as a Tool for Advancing Precision Immuno-oncology
Than, X. Y., Ong, T. T., & Chow, E. K. (2024) · World Scientific Annual Review of Cancer Immunology · doi:10.1142/s2972389224300019
Exploring the Anti-Tumor Effects of Brusatol in Aggressive B-Cell LymphomasPreprint
Szmyra, M., Haingartner, S., Jantscher, S., Bernhart, E. M., Kovács-Hajdu, P., Bošková, V., Krall, N., Zupo, A., Pircher, T., Pansy, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.649058
“Furthermore, drug response score (DRS) [33] analysis confirmed increased brusatol’s cytotoxic activity in samples with higher c-MYC expression after 24 (Fig.”
Self-citation
High Content Imaging Applications of Advanced and Translational Disease Models in Drug Discovery and Development
Cui, W., Haffa, M., Massai, F., Qian, K., Vallin, M., Axelsson, H., & Seashore-Ludlow, B. A. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837676941-00168
Ex vivo modeling of morphological, molecular and pharmacological tumor heterogeneity of metastatic colorectal cancerPreprint
Lothe, R., Kryeziu, K., Klokkerud, S. M. K., Totland, M. Z., Moosavi, S. H., Reims, H. M., Bergsland, C. H., Eilertsen, I. A., Smeby, J., Lassen, K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6507406/v1
Haemato-oncology
Horne, G. A., & Copland, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95311-5.00003-8
Personalized cancer treatments based on testing drugs quickly leads to faster treatment, better outcomes
Azzam, D. J. (2024) · doi:10.64628/aai.vh5wyp4ps
An ex vivo functional biomarker of treatment response in pediatric low-grade gliomaPreprint
Artz, N., Mann, B., Ebbs, A., Darawsheh, R., Dasari, R., Adefolaju, A., Bell, N., Trembath, D. G., Higgins, D. M. O., Elton, S., et al. (2025) · medRxiv · doi:10.1101/2025.09.11.25333944
Improving the Clinical Interpretability of Functional Drug Screens: A Suggestion for Standardized Clinical Decision Thresholds in Quadratic Phenotypic Optimization Platform
Pang, J. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00721
Additional file 2 of Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
Cartry, J., Bedja, S., Boilève, A., Mathieu, J. R. R., Gontran, E., Annereau, M., Job, B., Mouawia, A., Mathias, P., de Baère, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24439456
Additional file 4 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623358
Additional file 1 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623349
Additional file 3 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623355
Additional file 2 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623352
Additional file 6 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623364
Additional file 5 of SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Njouendou, A. J., Szarvas, T., Tiofack, A. A. Z., Kenfack, R. N., Tonouo, P. D., Ananga, S. N., Bell, E. H. M. D., Simo, G., Hoheisel, J. D., Siveke, J. T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623361
Cancer Theories
Paul, D. (2025) · Springer eBooks · doi:10.1007/978-3-032-08808-6_4 · Cited by 2
Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer
Labrosse, K. B., Lombardo, F. C., Bartoszek, E. M., Sauteur, L., Tanner, N., Tanna, T., Wolf, A., TUNKOVÁ, B., Kašíková, L., Fedier, A., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01321-4
“This approachhasdemonstratedutilityinexvivocultureplatformsacross bothsolidtumors 53,55,63,64 and hematologic malignancies 53,64 .”
Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugsPreprint
Wöhrl, L., Das, D., Weidele, K., Treitschke, S., Baron, C., Halbritter, D., Botteron, C., Lüke, F., Gužvić, N. S., Werner‐Klein, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704037
“Functional precision oncology is beginning to influence treatment decisions in hematologic malignancies ( 28, 32 ) and early data now suggest that similar strategies may be applied to solid tumors, further expanding the scope of functional testing beyond hematologic cancers ( 29, 30 ).”
Investigating the impact of adenomatous polyposis coli on T cell cytotoxicity : murine and human immuno-oncology models in microfluidic droplets
Bonnet, V. (2024) · theses.fr (ABES) · doi:10.70675/84b35e02z2164z4797za52eze31f4da3774d
Immunomodulation des lymphocytes Vγ9Vδ2 dans les leucémies aigües
Floch, A.-C. L. (2023) · theses.fr (ABES) · doi:10.70675/b4e332efz0a66z4c9az85eaz8eea012e9839
Drug response profiling guides precision therapy in relapsed and refractory childhood acute lymphoblastic leukemiaPreprint
Steffen, F. D., Lissat, A., Alten, J., Kriston, A., Scheidegger, N. K., Eckert, C., Bodmer, N., Schori, L. J., Schühle, S., Arpagaus, A., et al. (2026) · medRxiv · doi:10.64898/2026.04.08.26350164
Melanoma cell states define therapeutic vulnerabilities in a multimodal single-cell atlasPreprint
Levesque, M. P., Wegmann, R., Chevrier, S., Lehmann, K.-V., Prummer, M., Tusup, M., Gut, G., Casanova, R., Kuipers, J., Lischetti, U., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9413884/v1 · Cited by 1
Self-citation
A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia
Willoch, K., Zhao, Z., Durán, P. A., Mikaeloff, F., Struyf, N., Österroos, A., Lehmann, S., Kallioniemi, O., Saarela, J., Tyner, J. W., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01480-4 · Cited by 1
“4, 5).”
Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity
Kryeziu, K., Klokkerud, S. M. K., Totland, M. Z., Moosavi, S. H., Reims, H. M., Bergsland, C. H., Eilertsen, I. A., Smeby, J., Lassen, K., Lundesgaard, K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102840 · Cited by 3
Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia
Hermansen, J. U., Yin, Y., Tjønnfjord, G. E., Mato, A., & Skånland, S. S. (2026) · British Journal of Haematology · doi:10.1111/bjh.70603
Patient-derived tissue slice cultures from endoscopic biopsies as a translational ex vivo model for inflammatory bowel diseases
Werner, J., Schiller, L., Müller, C., Lehmann, J. O. R., Przybilla, J., Schlosser, T., Hoffmeister, A., Kallendrusch, S., & Vissiennon, C. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02209-0
“Notably in oncology, functional precision medicine approaches using ex vivo drug testing on patient-derived tissue have demonstrated predictive value for clinical outcomes [4 ].”
Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications
Sun, C., Wu, G., Wu, D., Du, Q., Lu, Q. W., Hu, W., Wang, J., xie, A., Yao, Z., Xia, M., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.06.041
Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy
Herzberg, F., Lu, F., Korenkov, M., Fregona, V., Didoss, C., Heisterkamp, N., Sprechert, M., Polici, A., Heck, C., Haas, S. F., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03047-5
Quality assessment of synthetic data in healthcare: a critical appraisal with a focus on subgroup bias
Chatzichristos, C., Katsimpokis, D., Lai, C., van Santvliet, L., Camarrone, F., Knoors, D., Geleijnse, G., Speybroek, M. V., Lewi, M., Vannieuwenhuyse, B., et al. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03719-3 · Cited by 1
Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies
Cederlund, A., Struyf, N., Pizarro, L. R., Östling, P., Sonnevi, K., Wahlin, B. E., & Erkers, T. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01630-8
“…in the assay requires further investigation, extensive resistance is reasonable in a heavily pre-treated cohort however other studies have shown mixed results for conventional chemotherapeutics using shorter incubations 12,25 potentially introducing a disproportionate disadvantage for these agents.”
Metabolomic and drug profiling of patient-derived glioblastoma models uncovers targetable vulnerabilities in IDH wild-type tumors
Ali, K. M., Monedeiro, F., Stanzer, S., BANDRES-MERIZ, J., Franz, J., Harbusch, N., Magnes, C., Zügner, E., Leoni, M., Asslaber, M., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02396-7
Integrating ex vivo platforms with AI to guide glioblastoma treatment
Bardhan, M., Paul, S., Pun, S., Aryal, M. R., Claudio, P. P., Binder, J., Barrile, R., & Krummel, D. P. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05708-y
“[54 ] GlioFlow3D: a scalable and physiologically relevant microphysiological platform MPSs integrate tissue engineering, biomaterials, and micro - fluidics to recreate key aspects of organ-level physiology in vitro [15, 16 ].”
High-content imaging workflow for single-cell drug response profiling of acute myeloid leukemia subtypes
Isigkeit, L., Sinderwald, R., Neumann, J., Ismaili, A., Hong, Y., & Oppermann, S. (2026) · SLAS DISCOVERY · doi:10.1016/j.slasd.2026.100337
Off-target drug repurposing for rare and ultra-rare cancers: towards a scalable therapeutic framework
Premaratne, G., & Ameratunga, M. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1921857

Authors: Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., Felsleitner-Hauer, V., Forte, M., Gaiger, A., Geissler, K., Greinix, H. T., Gstöttner, W., Hacker, M., Hartmann, B. L., Hauswirth, A. W., Heinemann, T., Heintel, D., Hoda, M. A., Hopfinger, G., Jaeger, U., Kazianka, L., Kenner, L., Kiesewetter, B., Krall, N., Krajnik, G., Kubicek, S., Le, T., Lubowitzki, S., Mayerhoefer, M. E., Menschel, E., Merkel, O., Miura, K., Müllauer, L., Neumeister, P., Noesslinger, T., Ocko, K., Öhler, L., Panny, M., Pichler, A., Porpaczy, E., Prager, G. W., Raderer, M., Ristl, R., Ruckser, R., Salamon, J., Schiefer, A.-I., Schmolke, A.-S., Schwarzinger, I., Selzer, E., Sillaber, C., Skrabs, C., Sperr, W. R., Srndic, I., Thalhammer, R., Valent, P., van der Kouwe, E., Vanura, K., Vogt, S., Waldstein, C., Wolf, D., Zielinski, C. C., Zojer, N., Simonitsch-Klupp, I., Superti-Furga, G., Snijder, B., & Staber, P. B.
Affiliations: Vienna General Hospital (AT)
Austrian Academy of Sciences (AT)
Medical University of Vienna (AT)
Klinikum Klagenfurt (AT)
8Abteilung für Innere Medizin, Krankenhaus der Barmherzigen Brüder Salzburg, Salzburg, Austria.
Universitätsklinikum Wiener Neustadt (AT)
Sigmund Freud Privatuniversität Wien (AT)
Medical University of Graz (AT)
Landeskrankenhaus Feldkirch (AT)
ETH Zurich (CH)
17Division of Medicine I, Klinik Ottakring, Vienna, Austria.
19Third Medical Department, Centre for Oncology and Haematology, Klinik Favoriten, Vienna, Austria.
Universitätsklinikum St. Pölten (AT)
Memorial Sloan Kettering Cancer Center (US)
Hanusch Hospital (AT)
Nihon University (JP)
St. Josef-Krankenhaus Wien (AT)
29Second Medical Department, Klinik Donaustadt, Vienna, Austria.
30Department of Medicine, Landesklinikum Waidhofen a.d. Ybbs, Waidhofen-Ybbs, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology (AT)
1Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Innsbruck Medical University (AT)
5Department of Pathology, Medical University of Vienna, Vienna, Austria.
3CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Corresponding author: Staber, Philipp B.
ORCID: Kornauth, Christoph
Pemovska, Tea
Vladimer, Gregory I.
Bergmann, Michael
Eichner, Ruth
Esterbauer, Harald
Exner, Ruth
Gaiger, Alexander
Geissler, Klaus
Hacker, Marcus
Hartmann, Bernd Lorenz
Heinemann, Tim
Hoda, Mir Alireza
Hopfinger, Georg
Kazianka, Lukas
Kenner, Lukas
Kiesewetter, Barbara
Krall, Nikolaus
Kubicek, Stefan
Le, Trang
Lubowitzki, Simone
Mayerhoefer, Marius E.
Merkel, Olaf
Miura, Katsuhiro
Müllauer, Leonhard
Neumeister, Peter
Panny, Michael
Pichler, Alexander
Porpaczy, Edit
Prager, Gerald W.
Ristl, Robin
Schiefer, Ana-Iris
Schwarzinger, Ilse
Selzer, Edgar
Sperr, Wolfgang R.
Valent, Peter
van der Kouwe, Emiel
Vanura, Katrina
Waldstein, Cora
Wolf, Dominik
Zielinski, Christoph C.
Snijder, Berend
Staber, Philipp B.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-10-11
Volume: 12
Issue: 2
Pages: 372-387
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-21-0538
PMC: PMC9762339
OpenAlex: W3205761999
Cited by: 206
References: 43
Citations by year: 2026: 36 · 2025: 47 · 2024: 45 · 2023: 46 · 2022: 29 · 2021: 3
FWCI: 20.21
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 123 d)
Locations: Cancer Discovery (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vienna Science and Technology Fund (LS16-034)
Austrian Science Fund (F4704-B20, F4711-B20, P27132-B20)
European Molecular Biology Organization (1543-2012, 733-2016)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_163961, PP00P3_194809, CRSII5_193832)
European Research Council
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: functional precision medicine, hematologic malignancies, high-content imaging, drug response prediction, progression-free survival, exceptional responders
MeSH terms: Progression-Free Survival, Adult, Aged, Aged, 80 and over, Austria, Female, Humans, Male, Middle Aged, Cohort Studies, Hematologic Neoplasms, Young Adult, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks